Stockreport

Mucopolysaccharidosis Market Analysis and Forecast Report, 2025-2035: Enzyme Replacement Therapies Lead While Gene Therapy Emerges as Next Frontier [Yahoo! Finance]

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)  (TAK) 
PDF Enzyme Replacement Therapies (ERTs) and novel gene therapy developments are enhancing treatment options, targeting enzyme deficiencies, and offering potential long-term [Read more]